APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cannabinoid-based Antitumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cannabinoid-based Antitumor Drug Market Analysis and Forecast 2026-2032

2 January 2026197 pages

Choose your research edition.

Industry ResearchCannabinoid-based Antitumor Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Cannabinoid-based Antitumor Drug Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Cannabinoid-based Antitumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cannabinoid-based Antitumor Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cannabinoid-based Antitumor Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Cannabinoid-based Antitumor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cannabinoid-based Antitumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cannabinoid-based Antitumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cannabinoid-based Antitumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cannabinoid-based Antitumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cannabinoid-based Antitumor Drug include Cannabics Inc., GW Pharmaceuticals, Jay Pharma, Medicanja Ltd, Tikun Olam and Valeant Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cannabinoid-based Antitumor Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cannabinoid-based Antitumor Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Cannabinoid-based Antitumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cannabinoid-based Antitumor Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cannabinoid-based Antitumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cannabinoid-based Antitumor Drug revenue, projected growth trends, production technology, application and end-user industry.

Cannabinoid-based Antitumor Drug Segment by Company

Cannabics Inc.

GW Pharmaceuticals

Jay Pharma

Medicanja Ltd

Tikun Olam

Valeant Pharmaceuticals

Cannabinoid-based Antitumor Drug Segment by Type

Chewing Medicine

Lozenge

Other

Cannabinoid-based Antitumor Drug Segment by Application

Clinics

Hospitals

Others

Cannabinoid-based Antitumor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cannabinoid-based Antitumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cannabinoid-based Antitumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cannabinoid-based Antitumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cannabinoid-based Antitumor Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cannabinoid-based Antitumor Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cannabinoid-based Antitumor Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cannabinoid-based Antitumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chewing Medicine Major Player Table 3. Lozenge Major Player Table 4. Other Major Player Table 5. Global Cannabinoid-based Antitumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Clinics Major Player Table 7. Hospitals Major Player Table 8. Others Major Player Table 9. Cannabinoid-based Antitumor Drug Industry Trends Table 10. Cannabinoid-based Antitumor Drug Industry Drivers Table 11. Cannabinoid-based Antitumor Drug Industry Opportunities and Challenges Table 12. Cannabinoid-based Antitumor Drug Industry Restraints Table 13. Global Cannabinoid-based Antitumor Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Cannabinoid-based Antitumor Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Cannabinoid-based Antitumor Drug Market Share by Region (2021-2026) Table 16. Global Cannabinoid-based Antitumor Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Cannabinoid-based Antitumor Drug Market Share by Region (2027-2032) Table 18. Global Cannabinoid-based Antitumor Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Cannabinoid-based Antitumor Drug Revenue Market Share by Players (2021-2026) Table 20. Global Cannabinoid-based Antitumor Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Cannabinoid-based Antitumor Drug Key Players Headquarters & Area Served Table 22. Global Cannabinoid-based Antitumor Drug Players, Product Type & Application Table 23. Global Cannabinoid-based Antitumor Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Cannabinoid-based Antitumor Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Cannabinoid-based Antitumor Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Cannabinoid-based Antitumor Drug Revenue Market Share by Type (2021-2026) Table 30. Global Cannabinoid-based Antitumor Drug Revenue Market Share by Type (2027-2032) Table 31. Global Cannabinoid-based Antitumor Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Cannabinoid-based Antitumor Drug Revenue Market Share by Application (2021-2026) Table 35. Global Cannabinoid-based Antitumor Drug Revenue Market Share by Application (2027-2032) Table 36. Cannabics Inc. Company Information Table 37. Cannabics Inc. Business Overview Table 38. Cannabics Inc. Cannabinoid-based Antitumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Cannabics Inc. Cannabinoid-based Antitumor Drug Product Portfolio Table 40. Cannabics Inc. Recent Development Table 41. GW Pharmaceuticals Company Information Table 42. GW Pharmaceuticals Business Overview Table 43. GW Pharmaceuticals Cannabinoid-based Antitumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. GW Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio Table 45. GW Pharmaceuticals Recent Development Table 46. Jay Pharma Company Information Table 47. Jay Pharma Business Overview Table 48. Jay Pharma Cannabinoid-based Antitumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Jay Pharma Cannabinoid-based Antitumor Drug Product Portfolio Table 50. Jay Pharma Recent Development Table 51. Medicanja Ltd Company Information Table 52. Medicanja Ltd Business Overview Table 53. Medicanja Ltd Cannabinoid-based Antitumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Medicanja Ltd Cannabinoid-based Antitumor Drug Product Portfolio Table 55. Medicanja Ltd Recent Development Table 56. Tikun Olam Company Information Table 57. Tikun Olam Business Overview Table 58. Tikun Olam Cannabinoid-based Antitumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Tikun Olam Cannabinoid-based Antitumor Drug Product Portfolio Table 60. Tikun Olam Recent Development Table 61. Valeant Pharmaceuticals Company Information Table 62. Valeant Pharmaceuticals Business Overview Table 63. Valeant Pharmaceuticals Cannabinoid-based Antitumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Valeant Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio Table 65. Valeant Pharmaceuticals Recent Development Table 66. North America Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 67. North America Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 68. North America Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 69. North America Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 70. North America Cannabinoid-based Antitumor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 71. North America Cannabinoid-based Antitumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 72. North America Cannabinoid-based Antitumor Drug Revenue by Country (US$ Million) & (2027-2032) Table 73. Europe Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 74. Europe Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 75. Europe Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 76. Europe Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 77. Europe Cannabinoid-based Antitumor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Europe Cannabinoid-based Antitumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 79. Europe Cannabinoid-based Antitumor Drug Revenue by Country (US$ Million) & (2027-2032) Table 80. China Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 81. China Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 82. China Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 83. China Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 84. Asia Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 85. Asia Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 86. Asia Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 87. Asia Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 88. Asia Cannabinoid-based Antitumor Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Asia Cannabinoid-based Antitumor Drug Revenue by Region (US$ Million) & (2021-2026) Table 90. Asia Cannabinoid-based Antitumor Drug Revenue by Region (US$ Million) & (2027-2032) Table 91. SAMEA Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 92. SAMEA Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 93. SAMEA Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 94. SAMEA Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 95. SAMEA Cannabinoid-based Antitumor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. SAMEA Cannabinoid-based Antitumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 97. SAMEA Cannabinoid-based Antitumor Drug Revenue by Country (US$ Million) & (2027-2032) Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Cannabinoid-based Antitumor Drug Image Figure 2. Global Cannabinoid-based Antitumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cannabinoid-based Antitumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chewing Medicine Image Figure 5. Lozenge Image Figure 6. Other Image Figure 7. Global Cannabinoid-based Antitumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Cannabinoid-based Antitumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Clinics Image Figure 10. Hospitals Image Figure 11. Others Image Figure 12. Global Cannabinoid-based Antitumor Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Cannabinoid-based Antitumor Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Cannabinoid-based Antitumor Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Cannabinoid-based Antitumor Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Cannabinoid-based Antitumor Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Cannabinoid-based Antitumor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Cannabinoid-based Antitumor Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Cannabinoid-based Antitumor Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Cannabinoid-based Antitumor Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Cannabinoid-based Antitumor Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Cannabinoid-based Antitumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032) Figure 25. North America Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032) Figure 26. North America Cannabinoid-based Antitumor Drug Revenue Share by Country (2021-2032) Figure 27. United States Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Cannabinoid-based Antitumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032) Figure 32. Europe Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032) Figure 33. Europe Cannabinoid-based Antitumor Drug Revenue Share by Country (2021-2032) Figure 34. Germany Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Cannabinoid-based Antitumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032) Figure 44. China Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032) Figure 45. Asia Cannabinoid-based Antitumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032) Figure 47. Asia Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032) Figure 48. Asia Cannabinoid-based Antitumor Drug Revenue Share by Region (2021-2032) Figure 49. Japan Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Cannabinoid-based Antitumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Cannabinoid-based Antitumor Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Cannabinoid-based Antitumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Chewing Medicine
  • Lozenge
  • Other
Applications
  • Clinics
  • Hospitals
  • Others
Companies covered
  • Cannabics Inc.
  • GW Pharmaceuticals
  • Jay Pharma
  • Medicanja Ltd
  • Tikun Olam
  • Valeant Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cannabinoid-based Antitumor Drug Market by Type
  3. 1.2.1 Global Cannabinoid-based Antitumor Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chewing Medicine
  5. 1.2.3 Lozenge
  6. 1.2.4 Other
  7. 1.3 Cannabinoid-based Antitumor Drug Market by Application
  8. 1.3.1 Global Cannabinoid-based Antitumor Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Clinics
  10. 1.3.3 Hospitals
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Cannabinoid-based Antitumor Drug Market Dynamics
  1. 2.1 Cannabinoid-based Antitumor Drug Industry Trends
  2. 2.2 Cannabinoid-based Antitumor Drug Industry Drivers
  3. 2.3 Cannabinoid-based Antitumor Drug Industry Opportunities and Challenges
  4. 2.4 Cannabinoid-based Antitumor Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cannabinoid-based Antitumor Drug Market Perspective (2021-2032)
  2. 3.2 Global Cannabinoid-based Antitumor Drug Growth Trends by Region
  3. 3.2.1 Global Cannabinoid-based Antitumor Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cannabinoid-based Antitumor Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Cannabinoid-based Antitumor Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cannabinoid-based Antitumor Drug Revenue by Players
  2. 4.1.1 Global Cannabinoid-based Antitumor Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Cannabinoid-based Antitumor Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cannabinoid-based Antitumor Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cannabinoid-based Antitumor Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cannabinoid-based Antitumor Drug Key Players Headquarters & Area Served
  7. 4.4 Global Cannabinoid-based Antitumor Drug Players, Product Type & Application
  8. 4.5 Global Cannabinoid-based Antitumor Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cannabinoid-based Antitumor Drug Market CR5 and HHI
  11. 4.6.3 2025 Cannabinoid-based Antitumor Drug Tier 1, Tier 2, and Tier 3
5 Cannabinoid-based Antitumor Drug Market Size by Type
  1. 5.1 Global Cannabinoid-based Antitumor Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cannabinoid-based Antitumor Drug Revenue by Type (2021-2032)
  3. 5.3 Global Cannabinoid-based Antitumor Drug Revenue Market Share by Type (2021-2032)
6 Cannabinoid-based Antitumor Drug Market Size by Application
  1. 6.1 Global Cannabinoid-based Antitumor Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cannabinoid-based Antitumor Drug Revenue by Application (2021-2032)
  3. 6.3 Global Cannabinoid-based Antitumor Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Cannabics Inc.
  2. 7.1.1 Cannabics Inc. Company Information
  3. 7.1.2 Cannabics Inc. Business Overview
  4. 7.1.3 Cannabics Inc. Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Cannabics Inc. Cannabinoid-based Antitumor Drug Product Portfolio
  6. 7.1.5 Cannabics Inc. Recent Developments
  7. 7.2 GW Pharmaceuticals
  8. 7.2.1 GW Pharmaceuticals Company Information
  9. 7.2.2 GW Pharmaceuticals Business Overview
  10. 7.2.3 GW Pharmaceuticals Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 GW Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio
  12. 7.2.5 GW Pharmaceuticals Recent Developments
  13. 7.3 Jay Pharma
  14. 7.3.1 Jay Pharma Company Information
  15. 7.3.2 Jay Pharma Business Overview
  16. 7.3.3 Jay Pharma Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Jay Pharma Cannabinoid-based Antitumor Drug Product Portfolio
  18. 7.3.5 Jay Pharma Recent Developments
  19. 7.4 Medicanja Ltd
  20. 7.4.1 Medicanja Ltd Company Information
  21. 7.4.2 Medicanja Ltd Business Overview
  22. 7.4.3 Medicanja Ltd Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Medicanja Ltd Cannabinoid-based Antitumor Drug Product Portfolio
  24. 7.4.5 Medicanja Ltd Recent Developments
  25. 7.5 Tikun Olam
  26. 7.5.1 Tikun Olam Company Information
  27. 7.5.2 Tikun Olam Business Overview
  28. 7.5.3 Tikun Olam Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Tikun Olam Cannabinoid-based Antitumor Drug Product Portfolio
  30. 7.5.5 Tikun Olam Recent Developments
  31. 7.6 Valeant Pharmaceuticals
  32. 7.6.1 Valeant Pharmaceuticals Company Information
  33. 7.6.2 Valeant Pharmaceuticals Business Overview
  34. 7.6.3 Valeant Pharmaceuticals Cannabinoid-based Antitumor Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Valeant Pharmaceuticals Cannabinoid-based Antitumor Drug Product Portfolio
  36. 7.6.5 Valeant Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Cannabinoid-based Antitumor Drug Revenue (2021-2032)
  2. 8.2 North America Cannabinoid-based Antitumor Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032)
  5. 8.3 North America Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Cannabinoid-based Antitumor Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032)
  9. 8.5 North America Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Cannabinoid-based Antitumor Drug Revenue by Country
  11. 8.6.1 North America Cannabinoid-based Antitumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cannabinoid-based Antitumor Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Cannabinoid-based Antitumor Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Cannabinoid-based Antitumor Drug Revenue (2021-2032)
  2. 9.2 Europe Cannabinoid-based Antitumor Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cannabinoid-based Antitumor Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cannabinoid-based Antitumor Drug Revenue by Country
  11. 9.6.1 Europe Cannabinoid-based Antitumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cannabinoid-based Antitumor Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cannabinoid-based Antitumor Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Cannabinoid-based Antitumor Drug Revenue (2021-2032)
  2. 10.2 China Cannabinoid-based Antitumor Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032)
  5. 10.3 China Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Cannabinoid-based Antitumor Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032)
  9. 10.5 China Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cannabinoid-based Antitumor Drug Revenue (2021-2032)
  2. 11.2 Asia Cannabinoid-based Antitumor Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cannabinoid-based Antitumor Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cannabinoid-based Antitumor Drug Revenue by Country
  11. 11.6.1 Asia Cannabinoid-based Antitumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cannabinoid-based Antitumor Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cannabinoid-based Antitumor Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cannabinoid-based Antitumor Drug Revenue (2021-2032)
  2. 12.2 SAMEA Cannabinoid-based Antitumor Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cannabinoid-based Antitumor Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cannabinoid-based Antitumor Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cannabinoid-based Antitumor Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cannabinoid-based Antitumor Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cannabinoid-based Antitumor Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cannabinoid-based Antitumor Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cannabinoid-based Antitumor Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cannabinoid-based Antitumor Drug Revenue by Country
  11. 12.6.1 SAMEA Cannabinoid-based Antitumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cannabinoid-based Antitumor Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cannabinoid-based Antitumor Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst